GlassScriptPhysician profile
Eric R Vernier
NPI 1174755110
$33,332.61
in general payments reported to CMS, 2019-2025
35 companies · $3,183 in 2025
The $3,183 reported for 2025 was more than what 83% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $4,314 · 2021: $2,264 · 2022: $2,258 · 2023: $7,008 · 2024: $4,195 · 2025: $3,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,828 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,088 · Consulting Fee: $450 · Education: $19.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,828.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,088.00 |
| Consulting Fee | $450.00 |
| Education | $19.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $12,410.38 | 2019-2023 | |
| Neurelis, INC. | $7,407.85 | 2020-2025 | Valtoco |
| Ucb, INC. | $3,558.29 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Ironshore Pharmaceuticals INC. | $1,440.70 | 2019-2024 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $1,255.33 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $1,112.93 | 2019-2025 | Qelbree, Qelbree |
| Corium, LLC | $959.57 | 2021-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $688.31 | 2019-2022 | |
| Tris Pharma INC | $529.41 | 2020-2025 | Dyanavel Xr |
| Aquestive Therapeutics, INC. | $454.85 | 2019-2022 | |
| Livanova USA, INC. | $442.50 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $437.02 | 2023-2025 | Daybue |
| Catalyst Pharmaceuticals, INC. | $411.91 | 2023-2025 | Fycompa |
| Collegium Pharmaceutical, INC. | $293.81 | 2025 | Jornay Pm |
| Sumitomo Pharma America, INC. | $286.94 | 2023-2024 | Aptiom |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $244.55 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $240.77 | 2020-2023 | Elaprase |
| Sk Life Science, INC. | $194.76 | 2020-2024 | |
| Noven Therapeutics, LLC | $114.29 | 2024-2025 | Xelstrym |
| Immedica Pharma US, INC. | $97.68 | 2022-2023 | |
| Neos Therapeutics, LP | $89.59 | 2019-2023 | Adzenys Xr-Odt |
| Aucta Pharmaceuticals, INC. | $79.63 | 2024-2025 | Motpoly Xr |
| Zogenix INC. | $78.68 | 2021 | |
| Biogen, INC. | $72.93 | 2019-2023 | Spinraza |
| Ns Pharma, INC. | $72.86 | 2021-2025 | Viltepso |
| Allergan, INC. | $62.59 | 2019-2022 | |
| Otter Pharmaceuticals, LLC | $58.37 | 2025 | Sympazan |
| Abbvie INC. | $52.82 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $45.14 | 2021 | |
| Cranial Technologies, INC | $29.21 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $28.76 | 2025 | |
| Biocodex, INC. | $28.03 | 2023 | Diacomit |
| Noven Pharmaceuticals, INC. | $21.49 | 2024 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $18.12 | 2025 | Relexxii |
| Adlon Therapeutics L.P. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Vernier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.